Sebastian Johannes Reinstadler1, Holger Thiele, Ingo Eitel. 1. aUniversity Heart Center Lübeck, Medical Clinic II, Department of Cardiology, Angiology and Intensive Care Medicine, University Lübeck, Lübeck, Germany bUniversity Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria.
Abstract
PURPOSE OF REVIEW: This review summarizes the currently available evidence for the use of cardiac magnetic resonance (CMR) imaging for risk stratifying patients after ST-elevation myocardial infarction (STEMI). RECENT FINDINGS: Growing evidence indicates that CMR imaging allows a comprehensive prognosis assessment in patients following STEMI. Multiple trials have shown that markers of cardiac dysfunction, especially left ventricular ejection fraction, are strongly predictive for clinical events beyond traditional risk factors. Recent data indicate that CMR can be an even more specific marker for the prediction of clinical prognosis by determining the extent of irreversible myocardial and microvascular damage for an individual patient. A multiparametric approach by CMR for optimized risk stratification allows exact infarct sizing and tissue characterization of the jeopardized and infarcted myocardium including microvascular injury. Many of these CMR parameters (infarct size, myocardial salvage, microvascular obstruction, intramyocardial hemorrhage) have demonstrated an incremental prognostic value in addition to clinical risk factors and left ventricular ejection fraction. SUMMARY: The comprehensive evaluation of STEMI patients by CMR imaging has the potential to provide incremental prognostic information for risk stratification beyond established clinical risk markers. In light of the lack of trials, however, designed to prospectively test the value of a CMR-guided therapeutic strategy in patients with STEMI, the use of CMR for risk stratification of the postinfarction patient awaits further validation and research.
PURPOSE OF REVIEW: This review summarizes the currently available evidence for the use of cardiac magnetic resonance (CMR) imaging for risk stratifying patients after ST-elevation myocardial infarction (STEMI). RECENT FINDINGS: Growing evidence indicates that CMR imaging allows a comprehensive prognosis assessment in patients following STEMI. Multiple trials have shown that markers of cardiac dysfunction, especially left ventricular ejection fraction, are strongly predictive for clinical events beyond traditional risk factors. Recent data indicate that CMR can be an even more specific marker for the prediction of clinical prognosis by determining the extent of irreversible myocardial and microvascular damage for an individual patient. A multiparametric approach by CMR for optimized risk stratification allows exact infarct sizing and tissue characterization of the jeopardized and infarcted myocardium including microvascular injury. Many of these CMR parameters (infarct size, myocardial salvage, microvascular obstruction, intramyocardial hemorrhage) have demonstrated an incremental prognostic value in addition to clinical risk factors and left ventricular ejection fraction. SUMMARY: The comprehensive evaluation of STEMI patients by CMR imaging has the potential to provide incremental prognostic information for risk stratification beyond established clinical risk markers. In light of the lack of trials, however, designed to prospectively test the value of a CMR-guided therapeutic strategy in patients with STEMI, the use of CMR for risk stratification of the postinfarction patient awaits further validation and research.
Authors: Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Dorothea Eisner; Laura Riepl; Mathias Pamminger; Benjamin Henninger; Agnes Mayr; Johannes P Schwaiger; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler Journal: Clin Res Cardiol Date: 2020-04-15 Impact factor: 5.460
Authors: Grigorios Korosoglou; Sorin Giusca; Nina P Hofmann; Amit R Patel; Tomas Lapinskas; Burkert Pieske; Henning Steen; Hugo A Katus; Sebastian Kelle Journal: ESC Heart Fail Date: 2019-04-25
Authors: Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Nicolas Hein; Mathias Pamminger; Benjamin Henninger; Agnes Mayr; Hans-Josef Feistritzer; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler Journal: J Am Heart Assoc Date: 2020-01-31 Impact factor: 5.501
Authors: Christina Tiller; Martin Reindl; Sebastian Johannes Reinstadler; Magdalena Holzknecht; Michael Schreinlechner; Alexander Peherstorfer; Nicolas Hein; Ivan Lechner; Agnes Mayr; Gert Klug; Bernhard Metzler Journal: BMC Cardiovasc Disord Date: 2019-12-09 Impact factor: 2.298
Authors: Christina Tiller; Magdalena Holzknecht; Martin Reindl; Ivan Lechner; Verena Kalles; Felix Troger; Johannes Schwaiger; Agnes Mayr; Gert Klug; Christoph Brenner; Axel Bauer; Bernhard Metzler; Sebastian Johannes Reinstadler Journal: Open Heart Date: 2021-02
Authors: Martin Reindl; Thomas Stiermaier; Ivan Lechner; Christina Tiller; Magdalena Holzknecht; Agnes Mayr; Johannes P Schwaiger; Christoph Brenner; Gert Klug; Axel Bauer; Holger Thiele; Hans-Josef Feistritzer; Bernhard Metzler; Ingo Eitel; Sebastian J Reinstadler Journal: Eur Heart J Open Date: 2021-11-09
Authors: Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Benjamin Henninger; Agnes Mayr; Christoph Brenner; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler Journal: JAMA Netw Open Date: 2020-06-01
Authors: Magdalena Holzknecht; Martin Reindl; Christina Tiller; Sebastian J Reinstadler; Ivan Lechner; Mathias Pamminger; Johannes P Schwaiger; Gert Klug; Axel Bauer; Bernhard Metzler; Agnes Mayr Journal: Clin Res Cardiol Date: 2021-04-21 Impact factor: 5.460